CoChat

Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction

Open access
Amorim, Ana M. B., Piochi, Luiz F., Gaspar, Ana T., Preto, António J., Rosário-Ferreira, Nícia, Moreira, Irina S. · 2024 · Chemical Research in Toxicology

The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.

Abstract

The attrition rate of drugs in clinical trials is generally quite high, with estimates suggesting that approximately 90% of drugs fail to make it through the process. The identification of unexpected toxicity issues during preclinical stages is a significant factor contributing to this high rate of failure. These issues can have a major impact on the success of a drug and must be carefully considered throughout the development process. These late-stage rejections or withdrawals of drug candidates significantly increase the costs associated with drug development, particularly when toxicity is detected during clinical trials or after market release. Understanding drug-biological target interactions is essential for evaluating compound toxicity and safety, as well as predicting therapeutic effects and potential off-target effects that could lead to toxicity. This will enable scientists to predict and assess the safety profiles of drug candidates more accurately. Evaluation of toxicity and safety is a critical aspect of drug development, and biomolecules, particularly proteins, play vital roles in complex biological networks and often serve as targets for various chemicals. Therefore, a better understanding of these interactions is crucial for the advancement of drug development. The development of computational methods for evaluating protein-ligand interactions and predicting toxicity is emerging as a promising approach that adheres to the 3Rs principles (replace, reduce, and refine) and has garnered significant attention in recent years. In this review, we present a thorough examination of the latest breakthroughs in drug toxicity prediction, highlighting the significance of drug-target binding affinity in anticipating and mitigating possible adverse effects. In doing so, we aim to contribute to the development of more effective and secure drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.chemrestox.3c00352

Cites

141 of 141 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 AI-driven drug development and toxicity forecasting, highlighting the use of AI in enhancing each stage of the drug development pipeline from target validation to approval and underscores its pivotal role in improving efficacy and safety by predicting toxicological risks.
Figure 1 AI-driven drug development and toxicity forecasting, highlighting the use of AI in enhancing each stage of the drug development pipeline from target validation to approval and underscores its pivotal role in improving efficacy and safety by predicting toxicological risks.CC BY · PubMed Central
Figure 2 Confluence of drug development and predictive technologies, illustrating the key aspects of drug development, highlighting (1) the role of proteomic data, (2) applications of artificial intelligence (AI) in drug discovery, (3) the Significance, limitations, and role of AI in toxicity prediction, and (4) the significance and challenges of in vivo reproducibility.
Figure 2 Confluence of drug development and predictive technologies, illustrating the key aspects of drug development, highlighting (1) the role of proteomic data, (2) applications of artificial intelligence (AI) in drug discovery, (3) the Significance, limitations, and role of AI in toxicity prediction, and (4) the significance and challenges of in vivo reproducibility.CC BY · PubMed Central
Figure 3 General and specific models in toxicity prediction, encompassing the model’s generality or specificity regarding predicted toxicity end points (lethal dose 50% (LD50), drug-induced liver injury (DILI), human ether-a-go-go-related gene (hERG inhibition), carcinogenesis, and Ames mutagenicity), along with its advantages and disadvantages.
Figure 3 General and specific models in toxicity prediction, encompassing the model’s generality or specificity regarding predicted toxicity end points (lethal dose 50% (LD50), drug-induced liver injury (DILI), human ether-a-go-go-related gene (hERG inhibition), carcinogenesis, and Ames mutagenicity), along with its advantages and disadvantages.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 141 references

Research works printed but not linked: 1

  1. Feng Q.; Dueva E.; Cherkasov A.; Ester M. PADME: A Deep Learning-Based Framework for Drug-Target Interaction Prediction. arXiv [cs.LG], 2018.

Cited by

Items 101–149 of 149

Metadata

Authors
Amorim, A. M. B., Piochi, L. F., Gaspar, A. T., Preto, A. J., Rosário-Ferreira, N., & Moreira, I. S.
Affiliations
  • Centro de Neurociências e Biologia Celular (PT)
  • CNC-UC─Center for Neuroscience and Cell Biology, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal
Corresponding author
Moreira, Irina S.
Venue
Chemical Research in Toxicology
Published
2024-05-17
Volume
37
Issue
6
Pages
827-849
ISSN
  • 0893-228X (ISSN-L)
  • 1520-5010
OpenAlex
W4397001794
Cited by
132
References
140
Citations by year
2026: 69 · 2025: 56 · 2024: 7
FWCI
3.69
Type
journal article
Language
en
Open access
Locations
  • Chemical Research in Toxicology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • European Regional Development Fund
  • Funda??o para a Ci?ncia e a Tecnologia (DSAIPA/DS/0118/2020, LA/P/0058/2020, SFRH/BD/144966/2019, UIDB/04539/2020, UIDP/04539/2020)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
drug toxicity prediction, drug safety, drug development attrition, protein-ligand interactions, drug binding affinity, off-target effects, computational toxicology, 3Rs, preclinical toxicity testing
MeSH terms
Drug Development, Animals, Humans, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.